Cargando…

Sustained Viral Suppression With Dolutegravir Monotherapy Over 192 Weeks in Patients Starting Combination Antiretroviral Therapy During Primary Human Immunodeficiency Virus Infection (EARLY-SIMPLIFIED): A Randomized, Controlled, Multi-site, Noninferiority Trial

BACKGROUND: Starting combination antiretroviral therapy (cART) during primary human immunodeficiency virus type 1 (HIV-1) infection results in a smaller HIV-1 latent reservoir, reduced immune activation, and less viral diversity compared to starting cART during chronic infection. We report results o...

Descripción completa

Detalles Bibliográficos
Autores principales:	West, Emily, Zeeb, Marius, Grube, Christina, Kuster, Herbert, Wanner, Katrin, Scheier, Thomas, Neumann, Kathrin, Jörimann, Lisa, Hampel, Benjamin, Metzner, Karin J, Kouyos, Roger D, Braun, Dominique L, Günthard, Huldrych F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552587/ https://www.ncbi.nlm.nih.gov/pubmed/37338148 http://dx.doi.org/10.1093/cid/ciad366

Ejemplares similares

Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks
por: Jörimann, Lisa, et al.
Publicado: (2023)

Dolutegravir Monotherapy as Maintenance Strategy: A Meta-Analysis of Individual Participant Data From Randomized Controlled Trials
por: Fournier, Anna L, et al.
Publicado: (2022)

Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients
por: Olearo, Flaminia, et al.
Publicado: (2019)

Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation
por: Braun, Dominique L., et al.
Publicado: (2020)

High Rates of Asymptomatic Mycoplasma genitalium Infections With High Proportion of Genotypic Resistance to First-Line Macrolide Treatment Among Men Who Have Sex With Men Enrolled in the Zurich Primary HIV Infection Study
por: Ring, Alexander, et al.
Publicado: (2022)

Emergence of Human Immunodeficiency Virus-1 Drug Resistance During the 3-Month World Health Organization-Recommended Enhanced Adherence Counseling Period in the CART-1 Cohort Study
por: Brown, Jennifer A, et al.
Publicado: (2021)

Spontaneous reactivation of latent HIV-1 promoters is linked to the cell cycle as revealed by a genetic-insulators-containing dual-fluorescence HIV-1-based vector
por: Kok, Yik Lim, et al.
Publicado: (2018)

Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018
por: Jaha, Bashkim, et al.
Publicado: (2023)

Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study
por: Hauser, Anthony, et al.
Publicado: (2020)

Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study
por: Spinner, Christoph D, et al.
Publicado: (2020)

Stable HIV‐1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study
por: Sculier, D, et al.
Publicado: (2018)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy
por: Surial, Bernard, et al.
Publicado: (2023)

Understanding the Decline of Incident, Active Tuberculosis in People With Human Immunodeficiency Virus in Switzerland
por: Zeeb, Marius, et al.
Publicado: (2023)

Monocyte-derived macrophages exhibit distinct and more restricted HIV-1 integration site repertoire than CD4(+) T cells
por: Kok, Yik Lim, et al.
Publicado: (2016)

Seroprofiling of Antibodies Against Endemic Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 in a Human Immunodeficiency Virus Cohort in Lesotho: Correlates of Antibody Response and Seropositivity
por: Brown, Jennifer A, et al.
Publicado: (2023)

T-Cell Exhaustion in HIV-1/Hepatitis C Virus Coinfection Is Reduced After Successful Treatment of Chronic Hepatitis C
por: Caraballo Cortés, Kamila, et al.
Publicado: (2023)

New Onset of Kaposi Sarcoma in a Human Immunodeficiency Virus-1-Infected Homosexual Man, Despite Early Antiretroviral Treatment, Sustained Viral Suppression, and Immune Restoration
por: von Braun, Amrei, et al.
Publicado: (2014)

A Novel Acute Retroviral Syndrome Severity Score Predicts the Key Surrogate Markers for HIV-1 Disease Progression
por: Braun, Dominique L., et al.
Publicado: (2014)

Factors Associated With Weight Gain in People Treated With Dolutegravir
por: Taramasso, Lucia, et al.
Publicado: (2020)

Editorial Commentary: The Irreversibility of HIV Drug Resistance
por: Kouyos, Roger D., et al.
Publicado: (2015)

A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells
por: Rindler, Audrey E., et al.
Publicado: (2021)

The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis
por: Marzel, Alex, et al.
Publicado: (2018)

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial
por: Llibre, Josep M, et al.
Publicado: (2022)

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial( )
por: Osiyemi, Olayemi, et al.
Publicado: (2022)

Cluster of Leptospirosis Acquired Through River Surfing in Switzerland
por: Schreiber, Peter W., et al.
Publicado: (2015)

Changing Trends in International Versus Domestic HCV Transmission in HIV-Positive Men Who Have Sex With Men: A Perspective for the Direct-Acting Antiviral Scale-Up Era
por: Salazar-Vizcaya, Luisa, et al.
Publicado: (2019)

Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV: The Swiss HIV Cohort Study
por: Schwenke, Johannes M, et al.
Publicado: (2023)

Factors Associated With Liver Steatosis in People With Human Immunodeficiency Virus on Contemporary Antiretroviral Therapy
por: Riebensahm, Carlotta, et al.
Publicado: (2022)

Assessing the potential impact of transmission during prolonged viral shedding on the effect of lockdown relaxation on COVID-19
por: Tepekule, Burcu, et al.
Publicado: (2021)

Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study
por: Hasse, Barbara, et al.
Publicado: (2014)

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks
por: Rolle, Charlotte-Paige, et al.
Publicado: (2023)

Impact of Obesity on the Drug–Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers
por: Berton, Mattia, et al.
Publicado: (2023)

HIV-1 integration sites in CD4(+) T cells during primary, chronic, and late presentation of HIV-1 infection
por: Kok, Yik Lim, et al.
Publicado: (2021)

Reply to correspondence ‘Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a “stochastic” process’ by Gonzalez et al., Retrovirology 2017
por: Oberle, Corinna S., et al.
Publicado: (2017)

sHIV-1 drug resistance in people on dolutegravir-based ART: Collaborative analysis of cohort studies
por: Loosli, Tom, et al.
Publicado: (2023)

Leukocyte Count and Coronary Artery Disease Events in People With Human Immunodeficiency Virus: A Longitudinal Study
por: Avery, Emma F, et al.
Publicado: (2023)

Phylodynamics on local sexual contact networks
por: Rasmussen, David A., et al.
Publicado: (2017)

Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide–Based Regimens
por: Batterham, Rachel L, et al.
Publicado: (2023)

Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial
por: Bevers, Lisanne A H, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bmnqmhrjfqrlst7oro42d8th42